News

InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuti ...
Pyoderma Gangrenosum Market Set For Expansion With Orphan Drug Designations And Pipeline Acceleration Delveinsight
In April 2025, the FDA granted orphan drug designation to spesolimab-sbzo for the treatment of pyoderma gangrenosum. This ...